[Code of Federal Regulations]
[Title 21, Volume 7]
[Revised as of April 1, 2001]
From the U.S. Government Printing Office via GPO Access
[CITE: 21CFR640.34]

[Page 92-93]
 
                        TITLE 21--FOOD AND DRUGS
 
          DEPARTMENT OF HEALTH AND HUMAN SERVICES--(Continued)
 
PART 640--ADDITIONAL STANDARDS FOR HUMAN BLOOD AND BLOOD PRODUCTS--Table of Contents
 
                            Subpart D--Plasma
 
Sec. 640.34  Processing.

    (a) Plasma. Plasma shall be separated from the red blood cells 
within 26 days after phlebotomy (within 40 days after phlebotomy when 
CPDA-1 solution is used as the anticoagulant), and shall be stored at -
18  deg.C or colder within 6 hours after transfer to the final 
container, unless the product is to be stored as Liquid Plasma.
    (b) Fresh Frozen Plasma. Fresh Frozen Plasma shall be prepared from 
blood collected by a single uninterrupted venipuncture with minimal 
damage to and minimal manipulation of the donor's tissue. The plasma 
shall be separated from the red blood cells, frozen solid within 6 hours 
after phlebotomy and stored at -18  deg.C or colder.
    (c) Liquid Plasma. Liquid Plasma shall be separated from the red 
blood cells within 26 days after phlebotomy (within 40 days after 
phlebotomy when CPDA-1 solution is used as the anticoagulant), and shall 
be stored at a temperature of 1 to 6  deg.C within 4 hours after filling 
the final container.
    (d) Platelet Rich Plasma. Platelet Rich Plasma shall be prepared 
from blood collected by a single uninterrupted venipuncture with minimal 
damage to and manipulation of the donor's tissue. The plasma shall be 
separated from the red blood cells by centrifugation within 4 hours 
after phlebotomy. The time and speed of centrifugation shall have been 
shown to produce a product with at least 250,000 platelets per 
microliter. The plasma shall be stored at a temperature between 20 to 24 
 deg.C or between 1 and 6  deg.C, immediately after filling the final 
container. A gentle and continuous agitation of the product shall be 
maintained throughout the storage period, if stored at a temperature of 
20 to 24  deg.C.
    (e) Modifications of Plasma. It is possible to separate Platelets 
and/or Cryoprecipitated AHF from Plasma. When these components are to be 
separated, the plasma shall be collected as described in Sec. 640.32 for 
Plasma.
    (1) Platelets shall be separated as prescribed in subpart C of part 
640, prior to freezing the plasma. The remaining plasma may be labeled 
as Fresh Frozen Plasma, if frozen solid within 6 hours after phlebotomy.
    (2) Cryoprecipitated AHF shall be removed as prescribed in subpart F 
of part 640. The remaining plasma shall be labeled ``Plasma, 
Cryoprecipitate Reduced.''
    (3) Plasma remaining after both Platelets and Cryoprecipitated AHF 
have been removed may be labeled ``Plasma, Cryoprecipitate Reduced.''
    (f) The final container. (1) The final container shall have no color 
added to the plastic and shall be transparent to permit visual 
inspection of the contents; any closure shall maintain a hermetic seal 
and prevent contamination of the contents.
    (2) The final container material shall not interact with the 
contents, under the customary conditions of storage and use, in such a 
manner as to have an adverse effect upon the safety, purity, potency, 
and effectiveness of the product.
    (3) Prior to filling, the final container shall be identified by 
number so as to relate it to the donor.
    (g) The final product. (1) The final product shall be inspected 
immediately after separation of the plasma and shall not be issued for 
transfusion if there is (i) any abnormality in color or physical 
appearance, or (ii) any indication of contamination.
    (2) With the exception of Platelet Rich Plasma and Liquid Plasma the 
final product shall be inspected for evidence of thawing or breakage at 
the time of issuance, however, the containers need not be stored in a 
manner that shows evidence of thawing if records of continuous 
monitoring of the storage temperature establish that the temperature 
remained at -18  deg.C or colder. If continuous monitoring of the 
product is not available, the final product shall be stored in a manner 
that will show evidence of thawing and shall not be issued if there is 
any evidence of thawing.

[[Page 93]]

    (3) No preservative shall be added to the final product.

[42 FR 59878, Nov. 22, 1977, as amended at 43 FR 34460, Aug. 4 1978; 48 
FR 13026, Mar. 29, 1983; 50 FR 4139, Jan. 29, 1985; 64 FR 45373, Aug. 
19, 1999; 66 FR 1836, Jan. 10, 2001]

Subpart E  [Reserved]